Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Confirmed relapsed and advanced chronic lymphocytic leukemia (CLL)~  * Binet stage B or C disease with rapid disease progression, enlarged lymph nodes and organs, or severe B-symptoms~* No prior non-response to fludarabine combination therapy~PATIENT CHARACTERISTICS:~* ECOG performance status 0-3~* Life expectancy \> 6 months~* No severe organ dysfunction~* No other prior or concurrent neoplasm, autoimmune hemolytic anemia, or thrombocytopenia~PRIOR CONCURRENT THERAPY:~* No more than three previous treatment regimens for CLL (fludarabine allowed)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- FCM (Type: ACTIVE_COMPARATOR): Fludarabine i.v. (25 mg/m2/d, d1-3) Cyclophosphamide i.v. (200 mg/m2/d, d1-3) Mitoxantrone i.v. (8 mg/m2, d1) q28d, max. 6 cycles
- FCM + G-CSF (Type: EXPERIMENTAL): Fludarabine i.v. (25 mg/m2/d, d1-3) Cyclophosphamide i.v. (200 mg/m2/d, d1-3) Mitoxantrone i.v. (8 mg/m2, d1) Filgrastim (G-CSF) s.c. (5 µg/kg/d beginning on day +6 until neutrophil recovery above 1500/µl.) q28d, max. 6 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).